Fig. 4
From: Fasudil attenuates aggregation of α-synuclein in models of Parkinson’s disease
Fasudil treatment does not affect weight, rotarod performance or overall survival of α-SynA53T mice. a 50 days after birth (DOB = day of birth) of α-SynA53T mice, Fasudil treatment with 10 mg/kg bw and 30 mg/kg bw was started. After 100 and 200 days, mice were tested on a rotarod (Rot). From day 220 on, rotarod was performed twice a week to monitor for onset of clinical symptoms of α-SynA53T mice. b, c Weight of α-SynA53T mice was monitored weekly. The last 10 weight measurements are displayed (b), as well as last weight at day of sacrifice (c). d, e Rotarod analysis of α-SynA53T mice treated with 10 mg/kg bw and 30 mg/kg bw Fasudil as compared to untreated α-SynA53T controls and wildtype controls. The last 10 rotarod performances before sacrifice are displayed for all animals in the respective treatment groups (d), as well as the last rotarod performance before sacrifice, showing no significant differences between α-SynA53T mice with regard to Fasudil treatment (e). f Survival of α-SynA53T mice treated with 10 mg/kg bw and 30 mg/kg bw Fasudil as compared to untreated α-SynA53T controls, showing no significant differences between the groups. All data are given as means ± SEM; n(wt ctrl) = 10, n(A53T ctrl) = 10, n(A53T Fas10) = 10, n(A53T Fas30) = 9; **p < 0.01, ***p < 0.001, n.s. = not significant; T-Test for comparisons between ctrl groups; ANOVA with Dunnett post-hoc test for multiple group comparisons between α-SynA53T groups